The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Trump’s tariffs on products from the EU and TK add to a big trade bill that will hit U.S. states, with Texas and California ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

On Super Bowl Sunday, many tuning into the big game saw a controversial ad from the telehealth company Hims & Hers. The ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Verizon VP of partnerships Nick Kelly joins the Marketer's Brief to discuss why the brand skipped a Super Bowl national ad in ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...